Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399948 | 0.89 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL23259460 | 0.84 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2451527 | 0.83 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL5337360 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL6963172 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL1706424 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4047968 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL1444780 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4049448 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL7340276 | 0.80 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CYP2A6 3084/4885ASIC3 1037/4885LOXL2 3866/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CYP2A6 3084/4885ASIC3 1037/4885LOXL2 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.